AVI Biopharma Inc. (AVII) is in the Pharma Industry

• Sort by
• View Related Content by Tag

• AVI BioPharma, Inc. Q2 2008 Earnings Call Transcript

  AVI BioPharma, Inc. AVII Q2 2008 Earnings Call Transcript

  Earnings calls 2008-08-11

  Tags: Call Transcript, Earnings, Seeking Alpha, AVI Biopharma Inc.

• AVI BioPharma, Inc.Q4 2007 Earnings Call Transcript

  AVI BioPharma, Inc.Q4 2007 Earnings Call Transcript

  Earnings calls 2008-03-12

  Tags: Call Transcript, Earnings, Seeking Alpha, Financial Accounting, Finance, AVI Biopharma Inc.

• AVI Biopharma Q3 2005 Earnings Conference Call Transcript (AVII)

  AVI Biopharma Q3 2005 Earnings Conference Call Transcript AVII

  Earnings calls 2005-11-04

  Tags: Call Transcript, Earnings, Seeking Alpha, Financial Accounting, Finance, AVI Biopharma Inc.

Additional Resources

• Multiple Insiders of AVI BIOPHARMA INC(NasdaqGM: AVII)bought Shares of Multiple Insiders.

  M2 PRESSWIRE-27 March 2008-InsiderCow.com: Multiple Insiders of AVI BIOPHARMA INC(NasdaqGM: AVII)bought Shares of Multiple InsidersC1994-2008 M2 COMMUNICATIONS LTD RDATE:27032008 Reported by InsiderCow.com at 2008-03-26 15:42:37 ET Multiple Insiders of AVI BIOPHARMA INC(NasdaqGM: AVII) bought 300,400...

  Articles 2008-03-27

• AVI Biopharma, Inc. Review in Progress.

  M2 PRESSWIRE-25 March 2008-Street Tips: AVI Biopharma, Inc. Review in ProgressC1994-2008 M2 COMMUNICATIONS LTD RDATE:25032008 Streetinvesting.com has now resumed our progressive review of AVI Biopharma, Inc. (NASDAQ:AVII) as it opened up $0.03 nearing its 52 week low of $1.00...

  Articles 2008-03-25

• (AVII) SqueezeTrigger Price is $5.061. There is $219,654,080.00 That Short Sellers Still Need To Cover.

  M2 PRESSWIRE-6 March 2008-BUYINS.NET: AVII SqueezeTrigger Price is $5.061. There is $219,654,080.00 That Short Sellers Still Need To CoverC1994-2008 M2 COMMUNICATIONS LTD RDATE:05032008 BUYINS.NET / www.squeezetrigger.com is monitoring AVI BIOPHARMA INC (NASDAQ:AVII) in real time and just received an...

  Articles 2008-03-06

• AVI BioPharma Completes Purchase of Building for GMP Manufacturing

  PORTLAND, Ore. -- Fourth graph, second complete sentence should read: AVI's lead NEUGENE antisense compound is designed to target cell proliferation disorders, including cardiovascular restenosis. (sted: AVI's lead NEUGENE antisense compound is designed to target cell proliferation disorders, including cardiovascular restenosis, cancer and polycystic kidney disease.) The corrected...

  Articles 2007-04-20

• In- Depth Research on AVI Biopharma Inc.

  M2 PRESSWIRE-11 April 2007-Biotech News: In- Depth Research on AVI Biopharma IncC1994-2007 M2 COMMUNICATIONS LTD RDATE:11042007 In- Depth Research on AVI Biopharma Inc (NASDAQ:AVII) AVI BioPharma, Inc., a biopharmaceutical company, engages in the development of therapeutic products based on...

  Articles 2007-04-11

• Shareholders alert for AVI Biopharma Inc.

  M2 PRESSWIRE-2 April 2007-Biotech News: Shareholders alert for AVI Biopharma IncC1994-2007 M2 COMMUNICATIONS LTD RDATE:02042007 Shareholders alert for AVI Biopharma Inc (NASDAQ:AVII) AVI BioPharma, Inc., a biopharmaceutical company, engages in the development of therapeutic products based on NEUGENE antisense...

  Articles 2007-04-02

• AVI Biopharma Inc. Announces Full Year and Fourth Quarter Results.

  M2 PRESSWIRE-15 March 2007-International Stock Targets: AVI Biopharma Inc. Announces Full Year and Fourth Quarter ResultsC1994-2007 M2 COMMUNICATIONS LTD RDATE:15032007 AVI Biopharma Inc. (Nasdaq:AVII) was down 4.44 today on just over 240,000 shares traded. AVI BioPharma, Inc. today...

  Articles 2007-03-15

• Obama denies knowing details of investments

  WASHINGTON AP -- Democratic presidential candidate Barack Obama said Wednesday he was not aware he had invested in two companies backed by some of his top donors and said he had done nothing to aid their business with the government. The Illinois senator faced questions about more...

  Articles 2007-03-08

• Research and Markets: Gain An Insight In To AVI Biopharma Inc

  DUBLIN, Ireland -- Research and Markets (http://www.researchandmarkets.com/reports/c49830) has announced the addition of "AVI BioPharma Inc - Deals and Alliances Report" to their offering The AVI BioPharma Inc Deals & Alliances Report contains the company's contact information, business summary, company details, tables, graphs and listings of...

  Articles 2007-02-06

• Investor Alert for Shareholders of AVI Biopharma Inc.

  M2 PRESSWIRE-4 December 2006-Biotech News: Investor Alert for Shareholders of AVI Biopharma IncC1994-2006 M2 COMMUNICATIONS LTD RDATE:04122006 Investor Alert for Shareholders of AVI Biopharma Inc (NASDAQ:AVII) AVI BioPharma formerly Antivirals develops therapeutic and gene-targeted treatments for cancer and heart...

  Articles 2006-12-04

• Research and Markets: Cytotoxic Therapies, Camptosar, Eloxatin and Xeloda Are Some of the Product Segments Analyzed Inside the 2006 Global Strategic Business Report On Colorectal Cancer Therapeutics

  DUBLIN, Ireland -- Research and Markets (http://www.researchandmarkets.com/reports/c46294) has announced the addition of Colorectal Cancer CRC Therapeutics - Global Strategic Business Report to their offering. This report analyzes the worldwide markets for Colorectal Cancer Therapeutics in US$ Million. The major product segments analyzed are Cytotoxic Therapies...

  Articles 2006-12-01

• Fundamental Review for AVI Biopharma Inc.

  M2 PRESSWIRE-10 November 2006-Biotech News: Fundamental Review for AVI Biopharma IncC1994-2006 M2 COMMUNICATIONS LTD RDATE:10112006 Fundamental Review for AVI Biopharma Inc (NASDAQ: AVII) AVI BioPharma formerly Antivirals develops therapeutic and gene-targeted treatments for cancer and heart disease. Its lead...

  Articles 2006-11-10

• Bellwether Report.com Acknowledges AVI Biopharma Inc.

  M2 PRESSWIRE-19 October 2006-bellwetherreport.com: Bellwether Report.com Acknowledges AVI Biopharma IncC1994-2006 M2 COMMUNICATIONS LTD RDATE:19102006 The Bellwether Report Takes Notice of AVI Biopharma Inc (Nasdaq:AVII) AVI BioPharma formerly Antivirals develops therapeutic and gene-targeted treatments for cancer and heart...

  Articles 2006-10-19

• Bellwether Report.com Wants Your Attention Directed to AVI Biopharma Inc.

  M2 PRESSWIRE-29 September 2006-bellwetherreport.com: Bellwether Report.com Wants Your Attention Directed to AVI Biopharma Inc.C1994-2006 M2 COMMUNICATIONS LTD RDATE:29092006 Bellwether Report Takes Notice of AVI Biopharma Inc. (NASDAQ:AVII) AVI BioPharma formerly Antivirals develops therapeutic and gene-targeted treatments for cancer...

  Articles 2006-09-29

• AVI BIOPHARMA MODIFIES HEPATITIS C VIRUS CLINICAL STUDY.

  AVI BioPharma, Inc. (Nasdaq:AVII), Portland, Ore., announced today that it has entered patients to fill two new cohorts to extend the duration of treatment with AVI-4065 in its hepatitis C virus HCV clinical trial. One cohort will be treated twice daily for 28 days...

  Articles 2006-09-01

• Bare Metal Stents and Drug Eluting Stents Are Segments under the Coronary Stents Umbrella inside Global Report For 2006

  DUBLIN, Ireland -- Research and Markets (http://www.researchandmarkets.com/reports/c41179) has announced the addition of Coronary Stents - Global Strategic Business Report to their offering. This report analyzes the worldwide markets for Coronary Stents in US$ Million. The major product segments analyzed are Bare Metal Stents, and Drug...

  Articles 2006-08-25

• Auriga Executes Strategic Alliance with Degussa Targeting Chronic Gastro-Intestinal Diseases.

  M2 PRESSWIRE-23 August 2006-InvestSource Inc.: Auriga Executes Strategic Alliance with Degussa Targeting Chronic Gastro-Intestinal DiseasesC1994-2006 M2 COMMUNICATIONS LTD RDATE:23082006 Stocks in the News: Auriga LaboratoriesTM, Inc. (OTC: ARGA), Alexza Pharmaceuticals Inc. (NASDAQ: ALXA), Valeant Pharmaceuticals International (NYSE: VRX), AVI Biopharma...

  Articles 2006-08-23